Methotrexate compared with tofacitinib for chronic plaque psoriasis
Compares methotrexate and tofacitinib taken by mouth in adults with plaque psoriasis.
Plain-language title generated from the registry record
Registry title: Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis
Key facts
- Where
- Lahore, PakistanSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07261306, who can take part
Where in Pakistan
- Lahore General HospitalLahore, PakistanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Lahore General Hospital
- Trial code
- NCT07261306
- Record updated
- 3 December 2025
- Original description
Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this studyRead full original descriptionShow less
Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis
Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this study
Inclusion: Patients aged 18- 70 years of either gender; Only patients with Psoriasis Area and Severity Index (PASI) score of 10 or above, and/or Body Surface Area (BSA) involvement of 10% or more, will be included; Duration of plaque psoriasis for at least 6 months prior to the study; Psoriasis that has not shown adequate response to topical therapies.
Exclusion: Participants currently receiving systemic corticosteroids, biologics, or any other immunosuppressive agents within 4 weeks prior to the start of the study will be excluded; Individuals with other forms of psoriasis or other significant dermatological conditions that might interfere with the assessment of psoriasis; Known hypersensitivity or contraindications to either methotrexate or tofacitinib; History of significant liver, kidney, hematologic/bleeding disorder, gastrointestinal/acid peptic disease, or immune system disorders.and any history of tuberculosis and malignancy; Pregnant or lactating women will not be eligible for the study.